Publications by authors named "Xue-Xian Yan"
[Clinical Practice of Lu-DOTATATE in the Treatment of Neuroendocrine Tumors].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
December 2022
Article Synopsis
- - Most neuroendocrine tumors (NETs) have high levels of somatostatin receptors (SSTR), making them suitable for targeted therapy using peptide receptor radionuclide therapy (PRRT), which has shown a better response rate and increased patient survival compared to traditional drug therapies.
- - The article highlights the clinical trial phase of PRRT in China, detailing crucial aspects such as patient selection, pre-treatment medications, administration methods, treatment cycles, potential side effects, and follow-up plans in line with international guidelines and clinical experience.
- - The authors aim to enhance understanding of PRRT among relevant professionals to improve its practical application and support ongoing clinical trials, ultimately benefiting real-world patients.
INrf2 tethering of the transcription factor Nrf2 in the cytosol prevents Nrf2 activation of antioxidant response element (ARE) mediated gene expression. This investigation was undertaken to determine if tethering affected Nrf2 degradation. Data is presented showing that Nrf2 is degraded by the ubiquitin-proteasome pathway.
View Article and Find Full Text PDF